Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | Starlite/ChEMBL | References |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 1 mg kg-1 | Compound was tested in vivo for adjuvant arthritis in rat | ChEMBL. | 15239665 |
ED50 (functional) | = 3.5 mg kg-1 | Effective dose in the yeast-induced pyresis model in rat | ChEMBL. | 15239665 |
IC50 (binding) | = 5.668 | Inhibitory concentration for Cyclooxygenase-2 (Prostaglandin G/H synthase 2) in human whole blood | ChEMBL. | 15603946 |
IC50 (binding) | = 2.15 uM | Inhibition concentration against cyclooxygenase-2(COX-2) in human whole blood | ChEMBL. | 15239665 |
IC50 (binding) | = 2.15 uM | Inhibition concentration against cyclooxygenase-2(COX-2) in human whole blood | ChEMBL. | 15239665 |
IC50 (binding) | > 100 uM | Inhibition concentration against cyclooxygenase-1 (COX-1) in human whole blood | ChEMBL. | 15239665 |
IC50 (binding) | > 100 uM | Inhibition concentration against cyclooxygenase-1 (COX-1) in human whole blood | ChEMBL. | 15239665 |
Inhibition (functional) | = 50 % | In vivo inhibition of hyperalgesia in rat at 3 mg/kg | ChEMBL. | 15239665 |
Log IC50 (binding) | = 5.6676 | Inhibitory concentration for Cyclooxygenase-2 (Prostaglandin G/H synthase 2) in human whole blood | ChEMBL. | 15603946 |
Ratio (binding) | > 46 | Ratio of inhibitory activity of the compound against cyclooxygenase- (COX-1) to that of cyclooxygenase- (COX-2) | ChEMBL. | 15239665 |
Ratio (binding) | > 46 | Ratio of inhibitory activity of the compound against cyclooxygenase- (COX-1) to that of cyclooxygenase- (COX-2) | ChEMBL. | 15239665 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.